
    
      Primary Outcome Measures:

      Progression-free survival(PFS) Secondary Outcome Measures: Overall response rate(ORR),
      overall survival(OS), quality of life(QOL),etc.

      Estimated Enrollment: 160 Study Start Date: August 2008 Estimated Study Completion Date:
      August 2010

      The patients will be randomized into the following two arms:

      Arm A: erlotinib 150mg once per day up to disease progression or intolerable toxicity.

      Arm B: Gemcitabine (1000mg/m2, IV,d1 and d8) plus Carboplatin (AUC=5, IV d1) repeated every 3
      weeks up to 4 cycles.
    
  